Denenicokin

DB12908InvestigationalProtein Based Therapies

Denenicokin is under investigation in clinical trial NCT01152788 (Phase II Study of Interleukin-21 (rIL-21) vs Dacarbazine (DTIC) in Patients With Metastatic or Recurrent Melanoma).

Mechanism: Pharmacologically active on Interleukin-21 receptor
Curator reviewed
Also known as: IL-21 recombinant · L-METHIONYL(HUMAN INTERLEUKIN-21) · Recombinant human IL-21 · RECOMBINANT HUMAN INTERLEUKIN 21
Code names: BMS-982470 · rIL-21

Resolves to

Compound

UNIIA4LY1V9F0HCAS716840-32-3

Targets

Q9HBE5IL21R

What you can answer from here — as of July 07, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

9Clinical trialsPhase, status and sponsor resolved per trial

8+ReferencesStructured and connected to the statements they support

Which drugs share a target with Denenicokin, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account